The Infectious Disease Advisor team will be covering emerging research and key takeaways from IDWeek 2026, as well as ...

In people living with HIV and advanced solid tumors who are receiving antiretroviral therapy, treatment with nivolumab plus cabozantinib is safe.

Products that promise relief from genital herpes are easy to order online, but none of them are approved to treat the infection.

During the 2024-2025 season, influenza vaccination effectively lowered the risk for hospitalization and severe inpatient outcomes among adults.

Quadrivalent HPV vaccination before pregnancy is associated with a lower risk for adverse pregnancy outcomes, including preterm birth.

The quadrivalent HPV vaccine provides durable immune responses and protects against cervical disease in women with HIV.

Updated recommendations were presented for the management of UTIs in infants and children younger than 5 years in a recent guideline.

Congenital TORCH infections appear to be associated with an increased risk for intellectual disability and autism.

Two respiratory syncytial virus (RSV) vaccines, RSVPreF3+AS01 and RSVpreF, were highly effective at preventing hospital admissions and death among older adults during the 2023 to 2024 season. These ...

The FDA has approved Hovilpri for immunocompromised adults with refractory mucocutaneous HSV lesions, offering a novel oral treatment.

The M72/AS01 TB vaccine was safe for virologically suppressed adults with HIV, with no severe vaccine-related AEs reported.

Adults hospitalized with CAP face high mortality rates, particularly those with unsuppressed HIV and tuberculosis.